ABBV-744 IN COMBINATION WITH IMMUNOTHERAPY - AN OVERVIEW

In Segment C, individuals will obtain ABBV-744 and oral navitoclax. In Segment D, participants will get ABBV-744 and ruxolitinib. Contributors will receive treatment right up until illness progression or maybe the individuals are unable to tolerate the study drugs.88 These preclinical studies supply paradigms for long run clinical trials in AML, an